双歧杆菌三联活菌散联合熊去氧胆酸对新生儿巨细胞病毒性肝炎的疗效

探讨双歧杆菌三联活菌散联合熊去氧胆酸对新生儿巨细胞病毒性肝炎的疗效，为该类患儿的治疗提供参考。

选取2020年3月至2023年2月我院收治的140例巨细胞病毒性肝炎新生儿为对象，按随机数表法将其随机分为对照组和试验组，各70例。对照组患儿以熊去氧胆酸及更昔洛韦治疗，试验组患儿以双歧杆菌三联活菌散联合熊去氧胆酸及更昔洛韦治疗。比较两组患儿的临床疗效、肝功能指标水平、肠道菌群分布、免疫球蛋白水平、炎症因子水平、不良反应发生率。

治疗后试验组患儿总有效率高于对照组[91.43%（64/70） vs 75.71%（53/70），χ² = 6.295，P = 0.012]。治疗后试验组患儿的肝功能指标[总胆红素（TBil）、直接胆红素（DBil）、谷丙转氨酶（ALT）]水平均低于对照组（均P＜0.05）。治疗后观察组患儿肠道双歧杆菌、乳杆菌数量高于对照组，而大肠埃希菌、粪肠球菌数量则低于对照组（均P＜0.05）。治疗后试验组患儿免疫球蛋白A（IgA）、免疫球蛋白G（IgG）、免疫球蛋白M（IgM）水平均高于对照组患儿（均P＜0.05）。治疗后试验组患儿干扰素诱导蛋白-10（IP-10）、抗瓜氨酸蛋白抗体（ACPA）、血友病因子（vWF）水平均低于对照组（均P＜0.05）。治疗期间试验组不良反应发生率低于对照组（8.57% vs 12.86%，P＜0.05）。

双歧杆菌三联活菌散联合熊去氧胆酸及更昔洛韦能够改善巨细胞病毒性肝炎新生儿的肝功能指标水平，提升机体免疫水平，抑制炎症因子表达，治疗安全性良好。

The efficacy of Triple Viable Bifidobacterium Powder combined with Ursodeoxycholic acid on neonatal cytomegalovirus hepatitis

ObjectiveTo observe the efficacy of Triple Viable Bifidobacterium Powder on neonatal cytomegalovirus hepatitis (CMVH), providing a reference for the treatment. MethodsA total of 140 neonates with CMVH admitted to our hospital from January 2020 to January 2023 were randomly divided into control group and observation group with 70 cases each. The control group was treated with Urodeoxycholic acid and Ganciclovir, while the observation group were given Triple Viable Bifidobacterium Powder combined with Ursodeoxycholic acid and Ganciclovir. The clinical efficacy, liver function index level, immunoglobulin level, intestinal flora amount, inflammatory factor level and adverse reaction rate were evaluated and compared between the two groups. ResultsAfter treatment, the total efficiency rate in observation group was higher than in control group [91.43% (64/70) vs 75.71%(53/70), χ2 = 6.295, P = 0.012]; the levels of total bilirubin (TBil), direct bilirubin (DBil) and glutamic transferase (GGT) in observation group were lower than those in the control group (all P＜0.05); the levels of immunoglobulin A (IgA), immunoglobulin G (IgG) and immunoglobulin M (IgM) in observation group were higher than those in control group (all P＜0.05); the levels of interferon induced protein 10 (IP-10), anticitrulline protein antibody (ACPA) and hemophilia factor (vWF) in observation group were lower than those in the control group (all P＜0.05). The incidence of adverse reactions in the observation group was lower than in the control group (8.57% vs 12.86%, P＜0.05). ConclusionTriple Viable Bifidobacterium powder combined with Ursodeoxycholic acid is effective in treating neonatal CMVH, which can improve the liver function index levels of patients, enhance the immune level of the body, inhibit the expression of inflammatory factors, and has good safety.